yes - i would imagine functional rescue would occur even in low doses - thus we may achieve ‘unofficial’ (?) efficacy readouts - or anecdotal patient reported benefits as early as this year if Dr Chen’s/LEI’s RP11 patients make up the Part 1 Cohort.
The more I read of this presentation the more I feel it should have been marked price sensitive - as there’s lots of new info here, with an improved content delivery style.
Pending IND approval, all 3x programs open up to shifting up a gear - I like the objective they used:
”Establish human safety of PYC’s platform technology”
This would headline PYC as a proven solution to the delivery challenge faced by the (RNA) therapeutics industry as a whole
